GH Research PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GHRS research report →
Range $38 – $65
Price Chart
About the company
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.
- CEO
- Velichka Valcheva
- IPO
- 2021
- Employees
- 73
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on GHRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.20B
- P/E
- -19.54
- PEG
- 0.78
- P/S
- 0.00
- P/B
- 3.68
- EV/EBITDA
- -14.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -19.40%
- ROIC
- -20.11%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-335,000+0.0%
- Op Income
- $-60,675,999
- Net Income
- $-48,257,999-23.9%
- EPS
- $-0.79-5.3%
- OCF Growth
- -3.0%
- FCF Growth
- -3.2%
- 52W High
- $31.44
- 52W Low
- $12.04
- 50D MA
- $21.56
- 200D MA
- $21.75
- Beta
- 1.32
- RSI (14)
- 36
- Avg Volume
- 292.24K
No earnings-call transcripts are available for GHRS yet.
- Free Float
- 74.2%
- Shares Outstanding
- 68.64M
- Float Shares
- 50.91M
of shares held by institutions
68 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynx1 Capital Management LP | 13.26M | ▲ 2.50M |
| Bvf Inc/Il | 8.65M | 0 |
| Ra Capital Management, L.P. | 7.64M | ▼ 39.88K |
| Fmr LLC | 6.48M | ▲ 505.90K |
| Rtw Investments, LP | 5.93M | 0 |
| Deep Track Capital, LP | 3.33M | ▲ 3.33M |
| Avoro Capital Advisors LLC | 1.80M | 0 |
| Foresite Capital Management Vi LLC | 940.49K | ▲ 625.00K |
| Siren, L.L.C. | 600.00K | ▲ 600.00K |
| Blackrock, Inc. | 529.08K | ▲ 48.79K |
| Eventide Asset Management, LLC | 475.00K | ▲ 475.00K |
| Manufacturers Life Insurance Company, The | 428.56K | ▲ 428.56K |
Held by 29 ETFs
Biggest fund positions in GHRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Schonharting Florian | other | 2,303 |
| Aug 11, 26 | Moore Duncan | other | 2,202 |
| Aug 11, 26 | Hanley Dermot John | other | 2,202 |
| Aug 11, 26 | Forer Michael | other | 100,000 |
| Aug 11, 26 | Forer Michael | other | 2,202 |
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GHRS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GHRS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Wall Street Analysts See a 128.66% Upside in GH Research (GHRS): Can the Stock Really Move This High?
zacks.com · Nov 20
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 13
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
globenewswire.com · Nov 13
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
seekingalpha.com · Oct 23
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net · Oct 3
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
seekingalpha.com · Sep 20
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 6
Why Is GH Research Stock Trading Higher on Thursday?
benzinga.com · Jul 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
